MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- AUROBINDO PHARMA - ADCOCK INGRAM (S. Africa)
AUROBINDO PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results
AUROBINDO PHARMA Change
Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More
ADCOCK INGRAM (S. Africa)
Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
Financials
 AUROBINDO PHARMA  ADCOCK INGRAM |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| AUROBINDO PHARMA Mar-18 |
ADCOCK INGRAM Jun-14 |
AUROBINDO PHARMA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 809 | 341 | - | |
| Low | Rs | 504 | 246 | - | |
| Sales per share (Unadj.) | Rs | 281.1 | 101.6 | - | |
| Earnings per share (Unadj.) | Rs | 41.4 | -25.6 | - | |
| Cash flow per share (Unadj.) | Rs | 50.9 | -21.2 | - | |
| Dividends per share (Unadj.) | Rs | 2.50 | 0 | - | |
| Dividend yield (eoy) | % | 0.4 | 0 | - | |
| Book value per share (Unadj.) | Rs | 199.4 | 79.7 | - | |
| Shares outstanding (eoy) | m | 585.88 | 168.78 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 2.3 | 2.9 | 80.7% | |
| Avg P/E ratio | x | 15.9 | -11.5 | -138.2% | |
| P/CF ratio (eoy) | x | 12.9 | -13.9 | -93.1% | |
| Price / Book Value ratio | x | 3.3 | 3.7 | 89.3% | |
| Dividend payout | % | 6.0 | 0 | - | |
| Avg Mkt Cap | Rs m | 384,630 | 49,605 | 775.4% | |
| No. of employees | `000 | 17.3 | 4.3 | 403.7% | |
| Total wages/salary | Rs m | 21,308 | 3,113 | 684.4% | |
| Avg. sales/employee | Rs Th | 9,500.7 | 3,993.6 | 237.9% | |
| Avg. wages/employee | Rs Th | 1,229.4 | 725.2 | 169.5% | |
| Avg. net profit/employee | Rs Th | 1,397.9 | -1,006.3 | -138.9% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 164,666 | 17,144 | 960.5% | |
| Other income | Rs m | 1,020 | 120 | 849.4% | |
| Total revenues | Rs m | 165,686 | 17,264 | 959.7% | |
| Gross profit | Rs m | 37,718 | -2,971 | -1,269.5% | |
| Depreciation | Rs m | 5,580 | 740 | 754.1% | |
| Interest | Rs m | 777 | 464 | 167.4% | |
| Profit before tax | Rs m | 32,380 | -4,055 | -798.5% | |
| Minority Interest | Rs m | 31 | -11 | -277.8% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 8,183 | 253 | 3,229.2% | |
| Profit after tax | Rs m | 24,229 | -4,320 | -560.9% | |
| Gross profit margin | % | 22.9 | -17.3 | -132.2% | |
| Effective tax rate | % | 25.3 | -6.2 | -404.4% | |
| Net profit margin | % | 14.7 | -25.2 | -58.4% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 121,878 | 12,557 | 970.6% | |
| Current liabilities | Rs m | 86,806 | 7,065 | 1,228.7% | |
| Net working cap to sales | % | 21.3 | 32.0 | 66.5% | |
| Current ratio | x | 1.4 | 1.8 | 79.0% | |
| Inventory Days | Days | 130 | 111 | 117.1% | |
| Debtors Days | Days | 68 | 124 | 55.2% | |
| Net fixed assets | Rs m | 81,037 | 7,319 | 1,107.2% | |
| Share capital | Rs m | 586 | 80 | 736.1% | |
| Net worth | Rs m | 116,804 | 13,456 | 868.0% | |
| Long term debt | Rs m | 4,512 | 4,729 | 95.4% | |
| Total assets | Rs m | 211,052 | 25,420 | 830.2% | |
| Interest coverage | x | 42.7 | -7.7 | -551.8% | |
| Debt to equity ratio | x | 0 | 0.4 | 11.0% | |
| Sales to assets ratio | x | 0.8 | 0.7 | 115.7% | |
| Return on assets | % | 11.8 | -15.2 | -78.1% | |
| Return on equity | % | 20.7 | -32.1 | -64.6% | |
| Return on capital | % | 27.4 | -19.8 | -138.1% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 19,548 | 1,463 | 1,335.8% | |
| From Investments | Rs m | -19,570 | -449 | 4,355.2% | |
| From Financial Activity | Rs m | 8,642 | 4,292 | 201.4% | |
| Net Cashflow | Rs m | 8,922 | 5,306 | 168.2% | |
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.71 Rs / ZAR
Compare AUROBINDO PHARMA With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare AUROBINDO PHARMA With: PFIZER JUBILANT LIFE SCIENCES FDC LTD. NOVARTIS SUN PHARMA
|
| |
Today's Market
Of Falling Stocks, Tumbling Rupee and Weakening Economy(Podcast)
Another week of slowdown in the markets over fears of a looming slowdown in the domestic and global economy continue.
Related Views On News
AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)
Aug 8, 2019 | Updated on Aug 8, 2019For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)
May 30, 2019 | Updated on May 30, 2019For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Dec 19, 2018 | Updated on Dec 19, 2018Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
This 60-Year Old Smallcap Company Could Be Our Next Recommendation (The 5 Minute Wrapup)
Aug 12, 2019My experience at the recent AGM of this smallcap company which has financials of any FMCG major.
Interest Rates Are Low. Buy Solid Dividend Stocks Instead (The 5 Minute Wrapup)
Aug 13, 2019The dividends paid by these stocks are helpful when interest rates are falling.
Smallcaps that Will Outperform in the Market Rebound (Profit Hunter)
Aug 12, 2019Only These Smallcaps Will Give Historic Returns in the Future.
My Top 3 Dividend Stocks to Buy Now (Profit Hunter)
Aug 19, 2019As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.
Chandrayaan 2 Heads to the Moon and It's Good News for These Stocks (The 5 Minute Wrapup)
Aug 14, 2019Why investors should take note of India's advantage as a low cost satellite launcher...
More|
| |
AUROBINDO PHARMA SHARE PRICE
Aug 23, 2019 (Close)
TRACK AUROBINDO PHARMA
- Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON AUROBINDO PHARMA
AUROBINDO PHARMA 5-YR ANALYSIS
COMPARE AUROBINDO PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.